Deal-Making

c/o BioCina

BioCina partners with GPN Vaccines against Streptococcus pneumoniae

BioCina will increase the manufacturing scale for recombinant whole-cell vaccine gamma-PNTM 25-fold as part of an expanded partnership with GPN Vaccines.  As per the agreement, contract development and manufacturing organization (CDMO) BioCina will mass produce batches of GPN’s vaccine at its Adelaide, Australia facility, which specializes in microbial cell culture systems such as E. coli.  “The partnership will achieve three main objectives, our process engineers will increase the manufacturing scale 25-fold, to enable large-scale GMP manufacture for Phase II clinical studies, developing…

triveni bio

Triveni Bio raises $92m to take on I&I disorders

Amagma Therapeutics and Modify Therapeutics have launched Triveni Bio, a biotech company dealing with the treatment of inflammation and immunity (I&I) disorders.  Led by Atlas Venture, and Cormorant Asset Management, the $92 million series A financing also saw investment from OrbiMed, Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, among others.  The funds will be used to support TRIV-509, the biotech company’s flagship program – an antibody that targets kallikreins 5 and 7 to treat diseases related to inflammation…

Novartis bids on bluebird’s next FDA PRV for $103m

As the FDA draws closer to a decision on bluebird bio’s sickle cell disease gene therapy, Novartis has purchased the firm’s priority review voucher (PRV) for $103 million.  Bluebird’s gene therapy lovotibeglogene autotemcel (lovo-cel) is currently under US Food and Drug Administration (FDA) review for sickle cell disease in patients 12 years and older, with a decision anticipated by December 20, 2023.  “The potential sale of a priority review voucher would provide an important source of non-dilutive capital for bluebird…

AstraZeneca forks out $245m to bolster gene therapy pipeline

AstraZeneca has announced an investment worth $245 million in French biotechnology company Cellectis with an aim to develop cell and gene therapy (CGT) products.   As per the agreement, the firm will use Cellectis’ gene editing technologies and manufacturing capabilities to design CGT products. The aim of this collaboration is to strengthen AstraZeneca’s growing offering in this space and meet the unmet needs in oncology, immunology and rare diseases.   Under the terms of the deal, 25 genetic targets have been…

Eli Lilly bags Beam’s licensing rights in Verve agreement for $250m

Eli Lilly and Company has acquired Beam Therapeutics’ opt-in rights to Verve Therapeutics’ gene therapy programs for cardiovascular disease. Under the terms of the deal, Lilly will give Beam an upfront payment of $200 million as well as a $50 million equity investment. Additionally, Beam is eligible to receive a further $350 million if specific clinical and regulatory milestones are met. With a potential $600 million in total payments, Beam said the deal will extend the firm’s cash runway to…

Medigene selects AGC to manufacture cancer cell therapy

CDMO AGC Biologics has agreed to support Medigene with their IND filing and clinical trials to treat cancer. Contract development and manufacturing organization (CDMO) AGC Biologics will use its cell and gene therapy (CGT) facility in Milan, Italy to provide Medigene with autologous production for its cell therapy candidate, which aims to treat cancer. Through this deal, the CDMO aims to manufacture Medigene’s lead product candidate, a TCR-T therapy that treats solid cancers for phase I clinical trials, and help the…

Rampart bags $85m in Series A financing round for non-viral gene therapies

Rampart Biosciences has raised $85 million in a Series A financing round, which builds on an initial $40 million seed investment from OrbiMed. Rampart, a Californian biotechnology startup firm focused on developing biologics, said the Series A financing round will be used to develop medicines “that aim to unburden patients from disease and their treatments.” The company’s total amount of funding has now reached a total of $125 million. Venture capital firm Forbion led the Series A funding round and…

Merck KGaA bolsters oncology pipeline with Hengrui partnership

Germany’s Merck has exclusive rights outside of China for Jiangsu Hengrui Pharmaceuticals’ PARP1 inhibitor HRS-1167 and antibody-drug conjugate (ADC) drug SHR-A1904. Under the terms of the deal, Chinese drugmaker Hengrui will receive an upfront payment from Merck of €160 million ($169 million). Additionally, there is potential for Hengrui to receive further payments dependent on specific milestones and royalties, which could take the payments to a total of up to €1.4 billion ($1.5 billion). The partnership sees Merck gain a worldwide…

Samsung Biologics strikes manufacturing and development deal with Kurma

Samsung Biologics will provide Kurma Partners’ portfolio companies with manufacturing, development, and de-risking services for biologics. Contract development manufacturing organization (CDMO) Samsung Biologics has entered into a multi-year agreement with European venture capital firm Kurma. While no financial details of the deal have been disclosed, Samsung Biologics will provide chemistry, manufacturing, and control (CMC) development services for Kurma’s portfolio companies to streamline Investigational New Drug (IND) processes. In addition, the partnership aims to de-risk uncertainties in CMC and advance the…

GSK forks out $85m for Hansoh gynecology cancer ADC

Hansoh Pharma has sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal ($85 million upfront), plus royalties on any sales. The antibody drug conjugate (ADC) candidate, HS-20089, targets B7-H4, a transmembrane glycoprotein in the B7 superfamily that is highly expressed in various cancers but limited in normal tissues. Hansoh has started a China Phase I clinical study of HS-20089 for gynecologic cancers, especially ovarian and endometrial cancers with possibilities in other solid tumors. Under the…